IL6 and metabolic syndrome: In Chedraui et al.’s study [43], an increase in IL-6 and a decrease in urokinase-type plasminogen activator levels in postmenopausal women have been introduced as the reasons for the effects of these hormonal changes on the occurrence of the MetS.